ABSTRACT
Identifying individuals as carriers of severe disease traits enables informed decision making about reproductive options. Although carrier screening has traditionally been based on ethnicity, the increasing ethnic admixture in the general population argues for the need for pan-ethnic carrier screening assays. Highly multiplexed mutation panels allow for rapid and efficient testing of hundreds of mutations concurrently. We report the development of the Pan-Ethnic Carrier Screening assay, a targeted sequencing assay for routine screening that simultaneously detects 461 common mutations in 91 different genes underlying severe, early-onset monogenic disorders. Mutation selection was aided by the use of an extensive mutation database from a clinical laboratory with expertise in newborn screening and lysosomal storage disease testing. The assay is based on the Affymetrix GeneChip microarray platform but generates genomic DNA sequence as the output. Analytical sensitivity and specificity, using genomic DNA from archived control cultures and from clinical specimens, was found to be >99% for all mutation types. This targeted sequencing assay has advantages over multiplex PCR and next-generation sequencing assays, including accuracy of mutation detection over a range of mutation types and ease of analysis and reporting of results.
Subject(s)
Ethnicity/genetics , Genetic Testing/methods , Mutation , Oligonucleotide Array Sequence Analysis/methods , Sequence Analysis, DNA/methods , Adult , DNA Mutational Analysis/methods , Female , Heterozygote , High-Throughput Nucleotide Sequencing , Humans , Polymerase Chain Reaction , Pregnancy , Prenatal Diagnosis/methods , Sensitivity and SpecificityABSTRACT
OBJECTIVE: Growth hormone (GH) is a protein hormone with important roles in growth and metabolism. The objective of this study was to investigate the metabolism of a human subject with severe GH deficiency (GHD) due to a PIT-1 gene mutation and the metabolic effects of GH therapy using Nuclear Magnetic Resonance (NMR)-based metabonomics. NMR-based metabonomics is a platform that allows the metabolic profile of biological fluids such as urine to be recorded, and any alterations in the profile modulated by GH can potentially be detected. DESIGN: Urine samples were collected from a female subject with severe GHD before, during and after GH therapy, and from healthy age- and sex-matched controls and analysed with NMR-based metabonomics. SETTING: The samples were collected at a hospital and the study was performed at a research facility. PARTICIPANTS: We studied a 17 year old female adolescent with severe GHD secondary to PIT-1 gene mutation who had reached final adult height and who had ceased GH therapy for over 3 years. The subject was subsequently followed for 5 years with and without GH therapy. Twelve healthy age-matched female subjects acted as control subjects. INTERVENTION: The GH-deficient subject re-commenced GH therapy at a dose of 1 mg/day to normalise serum IGF-1 levels. MAIN OUTCOME MEASURES: Urine metabolic profiles were recorded using NMR spectroscopy and analysed with multivariate statistics to distinguish the profiles at different time points and identify significant metabolites affected by GH therapy. RESULTS: NMR-based metabonomics revealed that the metabolic profile of the GH-deficient subject altered with GH therapy and that her profile was different from healthy controls before, and during withdrawal of GH therapy. CONCLUSION: This study illustrates the potential use of NMR-based metabonomics for monitoring the effects of GH therapy on metabolism by profiling the urine of GH-deficient subjects. Further controlled studies in larger numbers of GH-deficient subjects are required to determine the clinical benefits of NMR-based metabonomics in subjects receiving GH therapy.
Subject(s)
Dwarfism, Pituitary/drug therapy , Dwarfism, Pituitary/genetics , Dwarfism, Pituitary/urine , Human Growth Hormone/therapeutic use , Metabolome/drug effects , Metabolomics/methods , Transcription Factor Pit-1/genetics , Adolescent , Biomarkers, Pharmacological/metabolism , Biomarkers, Pharmacological/urine , Case-Control Studies , Dwarfism, Pituitary/metabolism , Female , Follow-Up Studies , Growth Charts , Hormone Replacement Therapy , Human Growth Hormone/deficiency , Humans , Mutation, Missense/physiology , Nuclear Magnetic Resonance, Biomolecular , Urinalysis/methodsABSTRACT
For more than four decades the cause of most type A influenza virus infections of humans has been attributed to only two viral subtypes, A/H1N1 or A/H3N2. In contrast, avian and other vertebrate species are a reservoir of type A influenza virus genome diversity, hosting strains representing at least 120 of 144 combinations of 16 viral hemagglutinin and 9 viral neuraminidase subtypes. Viral genome segment reassortments and mutations emerging within this reservoir may spawn new influenza virus strains as imminent epidemic or pandemic threats to human health and poultry production. Traditional methods to detect and differentiate influenza virus subtypes are either time-consuming and labor-intensive (culture-based) or remarkably insensitive (antibody-based). Molecular diagnostic assays based upon reverse transcriptase-polymerase chain reaction (RT-PCR) have short assay cycle time, and high analytical sensitivity and specificity. However, none of these diagnostic tests determine viral gene nucleotide sequences to distinguish strains and variants of a detected pathogen from one specimen to the next. Decision-quality, strain- and variant-specific pathogen gene sequence information may be critical for public health, infection control, surveillance, epidemiology, or medical/veterinary treatment planning. The Resequencing Pathogen Microarray (RPM-Flu) is a robust, highly multiplexed and target gene sequencing-based alternative to both traditional culture- or biomarker-based diagnostic tests. RPM-Flu is a single, simultaneous differential diagnostic assay for all subtype combinations of type A influenza viruses and for 30 other viral and bacterial pathogens that may cause influenza-like illness. These other pathogen targets of RPM-Flu may co-infect and compound the morbidity and/or mortality of patients with influenza. The informative specificity of a single RPM-Flu test represents specimen-specific viral gene sequences as determinants of virus type, A/HN subtype, virulence, host-range, and resistance to antiviral agents.
Subject(s)
Influenza A virus/genetics , Influenza in Birds/diagnosis , Influenza, Human/diagnosis , Pathology, Molecular/methods , Animals , Base Sequence , Birds , Cell Line , Chick Embryo , Gene Expression Profiling/methods , Gene Expression Regulation, Viral , Humans , Influenza A virus/classification , Influenza in Birds/virology , Influenza, Human/virology , Molecular Sequence Data , Oligonucleotide Array Sequence Analysis , Reproducibility of Results , Reverse Transcriptase Polymerase Chain Reaction , Sensitivity and Specificity , Sequence Analysis, DNA , Sequence Homology, Nucleic AcidABSTRACT
BACKGROUND: Growth hormone is an important regulator of post-natal growth and metabolism. We have investigated the metabolic consequences of altered growth hormone signalling in mutant mice that have truncations at position 569 and 391 of the intracellular domain of the growth hormone receptor, and thus exhibit either low (around 30% maximum) or no growth hormone-dependent STAT5 signalling respectively. These mutations result in altered liver metabolism, obesity and insulin resistance. METHODOLOGY/PRINCIPAL FINDINGS: The analysis of metabolic changes was performed using microarray analysis of liver tissue and NMR metabonomics of urine and liver tissue. Data were analyzed using multivariate statistics and Gene Ontology tools. The metabolic profiles characteristic for each of the two mutant groups and wild-type mice were identified with NMR metabonomics. We found decreased urinary levels of taurine, citrate and 2-oxoglutarate, and increased levels of trimethylamine, creatine and creatinine when compared to wild-type mice. These results indicate significant changes in lipid and choline metabolism, and were coupled with increased fat deposition, leading to obesity. The microarray analysis identified changes in expression of metabolic enzymes correlating with alterations in metabolite concentration both in urine and liver. Similarity of mutant 569 to the wild-type was seen in young mice, but the pattern of metabolites shifted to that of the 391 mutant as the 569 mice became obese after six months age. CONCLUSIONS/SIGNIFICANCE: The metabonomic observations were consistent with the parallel analysis of gene expression and pathway mapping using microarray data, identifying metabolites and gene transcripts involved in hepatic metabolism, especially for taurine, choline and creatinine metabolism. The systems biology approach applied in this study provides a coherent picture of metabolic changes resulting from impaired STAT5 signalling by the growth hormone receptor, and supports a potentially important role for taurine in enhancing beta-oxidation.
Subject(s)
Liver/metabolism , Magnetic Resonance Spectroscopy/methods , Receptors, Somatotropin/genetics , Adipose Tissue/metabolism , Animals , Insulin Resistance/genetics , Male , Metabolism , Mice , Mice, Inbred C57BL , Models, Biological , Obesity/genetics , Oligonucleotide Array Sequence Analysis/methods , STAT5 Transcription Factor/metabolism , Taurine/metabolismABSTRACT
Understanding the molecular basis for the many actions of growth hormone (GH) has been challenging because many of these actions are only evident in vivo. Recently, STAT5b has emerged as a key GH signaling intermediate in the regulation of postnatal growth, adiposity and sexual dimorphism of hepatic gene expression. This realization is based on targeted disruption or mutation of the GH receptor and its signaling components, together with clinical studies of GH-insensitive mutants. Microarray analysis of liver from GH receptor and signal transducer and activation of transcription 5b (STAT5b)-deleted mice have identified a range of relevant transcripts regulated by the Janus kinase 2/STAT5b signaling pathway. In addition, many transcripts are regulated independently of STAT5b, presumably as a result of PtdIns 3-kinase, extracellular-regulated kinase and Src signaling by this pleiotropic cytokine receptor.
Subject(s)
Growth Hormone/metabolism , Obesity/metabolism , Sex Characteristics , Animals , Humans , Liver/metabolism , STAT5 Transcription Factor/metabolismABSTRACT
Growth hormone receptor (GHR) has been demonstrated to be nuclear localized both in vivo and in vitro, but the significance of this observation has remained elusive. Here we show that nuclear GHR is strongly correlated with proliferative status in vivo by using a liver regeneration model. In vitro, nuclear translocation of the GH receptor is GH-dependent and appears to be mediated by the Importin system. Constitutive nuclear targeting of GHR in murine pro-B cells is associated with constitutive activation of STAT5, a transforming agent in lymphoma and other cell types. This activation is abrogated by inhibition of JAK2 and appears to be driven by autocrine murine GH action coupled with enhanced nuclear uptake of phospho-STAT5. Nuclear targeting induces dysregulated cell cycle progression in the pro-B cell line, associated with constitutive up-regulation of the proliferation inducers Survivin and Mybbp, the metastasis related Dysadherin, and other tumor markers. GHR nuclear-targeted cells generate aggressive metastatic tumors when injected into nude mice, which display nuclear localized GHR strikingly similar to that seen in human lymphomas. We conclude that aberrant nuclear localization of GHR is a marker of high proliferative status and is sufficient to induce tumorigenesis and tumor progression.
Subject(s)
Cell Nucleus/metabolism , Cell Proliferation , Cell Transformation, Neoplastic , Animals , Protein Transport , RatsABSTRACT
The growth hormone receptor (GHR) is a critical regulator of postnatal growth and metabolism. However, the GHR signaling domains and pathways that regulate these processes in vivo are not defined. We report the first knock-in mouse models with deletions of specific domains of the receptor that are required for its in vivo actions. Mice expressing truncations at residue m569 (plus Y539/545-F) and at residue m391 displayed a progressive impairment of postnatal growth with receptor truncation. Moreover, after 4 months of age, marked male obesity was observed in both mutant 569 and mutant 391 and was associated with hyperglycemia. Both mutants activated hepatic JAK2 and ERK2, whereas STAT5 phosphorylation was substantially decreased for mutant 569 and absent from mutant 391, correlating with loss of IGF-1 expression and reduction in growth. Microarray analysis of these and GHR(-/-) mice demonstrated that particular signaling domains are responsible for the regulation of different target genes and revealed novel actions of growth hormone. These mice represent the first step in delineating the domains of the GHR regulating body growth and composition and the transcripts associated with these domains.
Subject(s)
RNA, Messenger/metabolism , Receptors, Somatotropin/metabolism , Signal Transduction , Animals , Blotting, Northern , Blotting, Western , Cytoplasm/metabolism , DNA-Binding Proteins/metabolism , Densitometry , Exons , Gene Expression Regulation , Genotype , Homozygote , Immunoblotting , Immunoprecipitation , Insulin-Like Growth Factor I/metabolism , Mice , Mice, Transgenic , Milk Proteins/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Models, Genetic , Mutation , Obesity/genetics , Oligonucleotide Array Sequence Analysis , Organ Size , Phenotype , Protein Structure, Tertiary , RNA/metabolism , STAT5 Transcription Factor , Stem Cells/metabolism , Time Factors , Trans-Activators/metabolism , Up-RegulationABSTRACT
A vast amount of DNA and protein sequence is now available and a plethora of programs have been developed to analyse the data. The bewildering variety of analyses that can be performed via the World-Wide Web can deter researchers from applying bioinformatics to augment their traditional genetic research. Focusing on the inherited eye diseases, this paper provides a guide to the appropriate software required for identification of candidate genes through to the detection and analysis of mutations.